Chemopreventive Agent Development

The Chemopreventive Agent Development Research Group (CADRG) promotes and supports research on cancer preventive agent development, from preclinical studies to phase I clinical trials. The group’s projects aim to intercept the carcinogenic process by identifying and developing preventative agents with the potential to block, reverse, or delay the early stages of cancer. In addition, the group supports research on clinically translatable biomarkers that can be used to monitor tumor initiation and progression or assess efficacy of preventive interventions.

Read more About the Chemopreventive Agent Development Research Group.

Funding Opportunities

Grants

Clinical Trials

Staff

Cancer Prevention Clinical Trials Network (CP-CTNet)

A medical professional shakes hands with a patient seated on a examination table.

Research Centers develop and conduct early phase clinical trials to assess the preventive potential of agents and interventions of varying classes.

PREVENT Cancer Preclinical Drug Development Program (PREVENT)

The peer-reviewed research pipeline supports new prevention interventions and biomarkers headed toward clinical trials.

News and Events

DCP/PREVENT-funded Project Presentations at the 2022 AACR Annual Meeting
Date Posted: April 1, 2022

Vaccine to Prevent Hereditary Cancers Nears Human Trials
Date Posted: July 13, 2021